Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug PharmaphorumCelcuity has won FDA approval for gedatolisib - its first product - as a treatment for patients with a particular form of breast cancer.OncologyRead full story pharminent July 15, 2026 (Last updated: July 16, 2026) Pharmaphorum Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s Tau-Targeting Alzheimer’s Data Show Promise — and Raise QuestionsNext: J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push Related Stories Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026 Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026
